Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.01) EPS.

Other analysts also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. JMP Securities restated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Trading Down 3.6 %

Shares of NASDAQ ESPR opened at $1.59 on Tuesday. The firm has a market capitalization of $313.29 million, a PE ratio of -2.48 and a beta of 1.01. Esperion Therapeutics has a 1 year low of $1.57 and a 1 year high of $3.94. The firm’s 50-day moving average is $1.97 and its 200-day moving average is $2.08.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics during the third quarter worth about $606,000. Anson Funds Management LP bought a new stake in shares of Esperion Therapeutics during the third quarter worth about $540,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after purchasing an additional 295,378 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Esperion Therapeutics by 66.8% during the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after purchasing an additional 241,512 shares during the last quarter. Finally, Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.